See related letter by Akbari *et al.*, <http://breast-cancer-research.com/content/12/4/404>

We read with great interest the paper by Akbari and colleagues \[[@B1]\] in a recent issue of *Breast Cancer Research*. The authors reported on the absence of *RAD51C*mutations in 454 patients with *BRCA1/2*-negative familial breast cancer/ovarian cancer (BC/OC). In the initial report by Meindl and colleagues \[[@B2]\], *RAD51C*mutations were identified in 6 out of 480 patients with *BRCA1/2*-negative familial BC/OC. Interestingly, on the basis of histopathologic features, including intermediate grade (G2), estrogen receptor-positive (ER^+^), progesterone receptor-positive (PR^+^), and HER2-negative (HER2^-^) expression, *RAD51C*-associated BCs were found to be similar to *BRCA2*-associated BCs \[[@B2]\]. *BRCA2*is known to play a significant role in male BC (MBC); however, no occurrence of MBC was observed in the six *RAD51C*families described \[[@B2]\].

To investigate the role of *RAD51C*in MBC, we screened for *RAD51C*mutations in 97 MBC patients selected from our population-based series of 126 cases because they were previously found negative for *BRCA1/2*, *CHEK2*, *PALB2*, and *BRIP1*mutations \[[@B3],[@B4]\]. Notably, 25.8% of cases showed a positive first-degree family history of BC or OC or both. The majority of MBCs were invasive ductal carcinomas (74.5%), G2 (53.5%), ER^+^(90.7%), PR^+^(82.6%), or HER2^-^(85.4%). Overall, 66% of the MBCs showed an ER^+^/PR^+^/HER2^-^phenotype. All patients provided informed consent to the study. We carried out mutation screening of the nine exons and intron/exon boundaries of *RAD51C*by high resolution melting (HRM) analysis, a rapid closed-tube mutation scanning method with high sensitivity and specificity. Cases displaying abnormal profiles were evaluated by direct sequencing. Primers are available upon request.

We found no truncating *RAD51C*mutations. We identified a novel intronic variant, *IVS3 c.738-16G\>T*, in 1 out of 97 MBCs (1%). By *in silico*analysis, performed with Splice Site Prediction (BDGP, Berkeley Drosophila Genome Project, Lawrence Berkeley National Laboratory, Berkeley, CA, USA) and NetGene 2 Server software (CBSA, Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark), the *IVS3 c.738-16G\>T*variant is predicted not to affect splicing. This variant was also identified in 2 out of 173 (1.2%) population controls examined. We also found a neutral polymorphic intronic variant, *IVS6 c.904+34T\>C*(rs28363318), in 16 out of 97 (16.5%) MBCs.

Overall, our results, which are based on a relatively large MBC series, are consistent with the findings by Akbari and colleagues \[[@B1]\] and with data on 92 patients with hereditary gynecological cancer in which no deleterious *RAD51C*mutations were identified \[[@B5]\] and would suggest that the impact of *RAD51C*mutations on BC predisposition might be more limited than initially reported. In conclusion, we found no evidence that *RAD51C*mutations may contribute to MBC susceptibility. Further studies on larger MBC series are needed to confirm our findings.
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